Raltegravir

DB06817ApprovedInvestigationalSmall moleculeHIV Integrase InhibitorsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor

Raltegravir is an antiretroviral agent used for the treatment of HIV infections in conjunction with other antiretrovirals. Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection.

Chemical structure of Raltegravir
Mechanism
Curator reviewed
Primary indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.Curator reviewed · 3 structured indications
Formula / weight
C20H21FN6O5 · 444.4163 g/mol (avg)
First approval
Canada, 2009 · United States, 2007 · European Union, 2020
Brand names
  • Isentress

Resolves to

Compound
UNII22VKV8053UCAS518048-05-0ChEMBLCHEMBL254316ChEBI82960PubChem54671008KEGGD06676
Clinical / RWD
RxNorm719872ATCJ05AJ01ATCJ05AR16
Structure
InChIKeyCZFFBEXEKNGXKS-UHFFFAOYSA-NSMILESCN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Targets
Q7ZJM1polP03366gag-pol

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
706Drug interactionsStructured to mechanism, not free text
Sign in
128Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
56Marketed productsAcross 9 countries and 22 labellers
Sign in
2ATC codesIncluding every combination product, plus 18 drug categories
Sign in
23+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Raltegravir, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In